278 material Form 8-K filings that 243 companies we cover made with the SEC in May 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Digi International reported second fiscal quarter 2024 revenue of $108 million, down 3% from a year earlier, and net income of $4 million, down from $6 million. The company lowered its fiscal 2024 Adjusted EBITDA range and now projects revenue down 5% year over year, citing customers who are more cautious on second half demand and longer sales cycles.
Q2 revenue was $108 million, down 3%; diluted EPS was $0.11 versus $0.16, and adjusted diluted EPS was $0.49, flat year over year
Company accrued an approximate $6 million liability for pending litigation in the quarter
Fiscal 2024 revenue is projected to be down 5% year over year; Adjusted EBITDA range lowered slightly
Third quarter revenue guidance is $103 million to $107 million, with adjusted diluted EPS of $0.47 to $0.51
Corcept Therapeutics reported first quarter 2024 revenue of $146.8 million, up 39 percent from a year earlier, and net income of $27.8 million, compared with $15.9 million in the first quarter of 2023. The company raised its 2024 revenue guidance to $620 million to $650 million from $600 million to $630 million, which points to stronger expected sales for the year.
Q1 2024 revenue of $146.8 million vs. $105.7 million in Q1 2023; diluted EPS $0.25 vs. $0.14
2024 revenue guidance raised to $620 million to $650 million from $600 million to $630 million
Operating expenses rose to $117.3 million from $90.8 million, driven by clinical trial activity and commercial team expansion
Cash and investments were $451.0 million at March 31, 2024, up from $425.4 million at December 31, 2023
Vita Coco reported first quarter 2024 net sales up 2% to $112 million, with net income of $14 million, or $0.24 per diluted share, compared with $7 million, or $0.12, a year earlier. The company raised its full-year 2024 guidance to net sales of $500 million to $510 million and Adjusted EBITDA of $76 million to $82 million, but said higher ocean freight costs will weigh on gross margins starting in the second quarter.
Q1 2024 net sales rose 2% to $112 million, and gross margin rose to 42.2% from 30.7%.
Q1 2024 Adjusted EBITDA was $21 million, compared with $9 million in the same period of 2023.
2024 guidance: net sales of $500 million to $510 million, Adjusted EBITDA of $76 million to $82 million, and full-year gross margin of 37% to 39%.
TG Therapeutics reported first quarter 2024 total revenue of $63.5 million, up from $7.8 million a year earlier, and a net loss of $10.7 million, down from $39.2 million. The company raised its full-year 2024 U.S. BRIUMVI net product revenue target to $270 million to $290 million, from $220 million to $260 million previously.
Q1 2024 total revenue of $63.5 million, including a $12.5 million milestone payment tied to the first EU launch of BRIUMVI in Germany
Q1 2024 U.S. BRIUMVI net product revenue of $50.5 million; company targets approximately $65 million for Q2 2024
Net loss of $10.7 million, or $0.07 per share, versus $39.2 million, or $0.28 per share, in Q1 2023
Cash, cash equivalents and investment securities of $209.8 million as of March 31, 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.